Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Blood

• Publication date

  1987-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V69.5.1280.BLOODJOURNAL6951280PMID 3471281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

  1986cited by this paper
• Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.

  1985cited by this paper
• Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.

  1985cited by this paper
• Chronic myelogenous leukemia: recent advances.

  1985cited by this paper
• Prognostic discrimination in "good-risk" chronic granulocytic leukemia

  1984cited by this paper
• Alpha interferon for induction of remission in hairy-cell leukemia.

  1984cited by this paper
• Cytogenetic studies of early myeloid progenitor compartments in Ph1- positive chronic myeloid leukemia. II. Long-term culture reveals the persistence of Ph1-negative progenitors in treated as well as newly diagnosed patients

  1984cited by this paper
• Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

  1984cited by this paper
• Interferons in the treatment of human cancer.

  1984cited by this paper
• Response of chronic myelogenous leukemia patients to COAP—splenectomy. A southwest oncology group study

  1984cited by this paper
• Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

  1984cited by this paper
• Renal cell carcinoma: antitumor effects of leukocyte interferon.

  1983cited by this paper
• Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.

  1983cited by this paper
• Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

  1983cited by this paper
• Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

  1982cited by this paper
• New approaches in chronic granulocytic leukemia--origin, prognosis, and treatment.

  1982cited by this paper
• New approaches in chronic granulocytic leukemia--origin, prognosis, and treatment.

  1982cited by this paper
• Growth characteristics of leukemic and normal hematopoietic cells in Ph' + chronic myelogenous leukemia and effects of intensive treatment.

  1982cited by this paper
• A multivariate analysis of prognostic factors in chronic myeloid leukemia.

  1982cited by this paper
• Chronic myelogenous leukemia--new concepts (second of two parts).

  1981cited by this paper
• Chronic myelogenous leukemia--new concepts (first of two parts).

  1981cited by this paper
• Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma.

  1980cited by this paper
• Human leukocyte interferon preparation blocks granulopoietic differentiation

  1979cited by this paper
• Human leukocyte interferon preparation blocks granulopoietic differentiation.

  1979cited by this paper
• Hematologic and cytologic characterization of 8/21 translocation acute granulocytic leukemia.

  1979cited by this paper
• Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).

  1979cited by this paper
• Evaluation of survival data for chronic myelocytic leukemia

  1976cited by this paper
• Chronic granulocytic leukemia.

  1976cited by this paper
• Survival in chronic myelogenous leukemia: Influence of treatment and extent of disease at diagnosis

  1973cited by this paper
• Granulocytic leukemia in whitehanded gibbons.

  1973cited by this paper
• Survival in chronic granulocytic leukemia. Splenic irradiation vs busulfan.

  1973cited by this paper
• Studies of cellular proliferation in human leukemia. VI. The proliferative activity, generation time, and emergence time of neutrophilic granulocytes in chronic granulocytic leukemia

  1970cited by this paper
• Cell-free transmission of murine myeloid leukaemia.

  1970cited by this paper
• Chronic granulocytic leukemia.

  1970cited by this paper
• Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy.

  1970cited by this paper
• Cyclic leucocytosis as evidence for retention of normal homoeostatic control in chronic granulocytic leukaemia.

  1967cited by this paper
• A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

  1965cited by this paper
• Virus interference. I. The interferon

  1957cited by this paper
• CHRONIC MYELOGENOUS LEUKEMIA: AGE INCIDENCE, DURATION, AND BENEFIT DERIVED FROM IRRADIATION

  1924cited by this paper

• Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)

  2026cites this paper
• An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies.

  2026cites this paper
• Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

  2024cites this paper
• Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

  2023cites this paper
• Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

  2022cites this paper
• Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia

  2021cites this paper
• Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation

  2021cites this paper
• Tyrosine kinase inhibitors and interferon‐α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines

  2020cites this paper
• Mechanisms of IFNalpha-1a-Induced Apoptosis in a Laryngeal Cancer Cell Line

  2019cites this paper
• C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cells.

  2019cites this paper
• C/EBP b is a critical mediator of IFN- a – induced exhaustion of chronic myeloid leukemia stem cells

  2019cites this paper
• Curcumin induces apoptosis in human leukemic cell lines through an IFIT2-dependent pathway

  2017cites this paper
• Chronic myeloid leukemia and cancer

  2017cites this paper
• Long-Term Outcomes of Tyrosine Kinase Inhibitors Treatment for Chronic Myeloid Leukemia

  2017cites this paper
• Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

  2017cites this paper
• A study of the chicken IFN lambda system

  2016cites this paper
• Regulatory mechanisms contributing to the homeostasis of normal and malignant hematopoietic cells

  2016cites this paper
• Ciblage de l'activité de l'interféron alpha : de la preuve de concept à l'activité biologique

  2016cites this paper
• The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

  2016cites this paper
• Immunotherapy Approaches in Cancer Treatment.

  2015cites this paper
• Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

  2015cites this paper
• Valutazione di costo-efficacia di ponatinib nella terapia della leucemia mieloide cronica in Italia

  2015cites this paper
• The interferon-alpha revival in CML

  2015cites this paper
• Treatment Development of Chronic Myeloid Leukemia

  2015cites this paper
• Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy

  2015cites this paper
• Qualitative and Quantitative Evaluation of the BCR-ABL Fusion Gene in Chronic Myelogenous Leukemia by Flourescence In Situ Hybridization and Molecular Genetic Methods

  2015cites this paper
• IFNA2: The prototypic human alpha interferon.

  2015cites this paper
• The treatment of chronic myeloid leukemia: A single-center, 20-year experience

  2014cites this paper
• VEGF in chronic myeloid leukemia treated with interferon and imatinib.

  2014cites this paper
• Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use

  2014cites this paper
• CENTRO UNIVERSITÁRIO DE BRASÍLIA - UNICEUB FACULDADE DE CIÊNCIAS DA EDUCAÇÃO E SAÚDE - FACES GRADUAÇÃO EM BIOMEDICINA

  2013cites this paper
• leukemia trials with interferon-alpha (letter) comparative analysis of the Italian and German chronic myeloid Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a

  2013cites this paper
• Novel approaches for the isolation and expansion of cytomegalovirus-specific T cells for adoptive immunotherapy

  2013cites this paper
• CENTRO UNIVERSITÁRIO DE BRASÍLIA - UNICEUB FACULDADE DE CIÊNCIAS DA EDUCAÇÃO E SAÚDE - FACES GRADUAÇÃO EM BIOMEDICINA

  2013cites this paper
• DRUG SELECTION PERSPECTIVES

  2013cites this paper
• Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Interferon, and Allogeneic Bone Marrow Transplantation in Treating the An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea,

  2013cites this paper
• the use and interpretation of monitoring methods modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on Monitoring the response and course of chronic myeloid leukemia in the

  2013cites this paper
• JAK2V617F-positive Myeloproliferative Neoplasms : KI mouse models, Interferon-α therapy and clonal architecture

  2013cites this paper
• New roles of STAT5 factors in chronic myeloid leukemia cell maintenance

  2013cites this paper
• Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

  2012cites this paper
• The Potential of Interferons in Malignant Disease

  2012cites this paper
• Research on and clinical importance of duplications in various chromosomal regions in addition to Philadelphia chromosome in chronic myeloid leukemia.

  2012cites this paper
• Myeloproliferative Neoplasms: Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis

  2012cites this paper
• Morphologic Changes in the Bone Marrow in Patients of Chronic Myeloid Leukemia (CML) Treated with ImatinibMesylate

  2012cites this paper
• Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

  2012cites this paper
• Major Therapeutic Uses of Interferons

  2012cites this paper
• Interferon treatment in patients with hypereosinophilia.

  2011cites this paper
• Cancer immunotherapy.

  2011cites this paper
• myelogenous leukemia in marrow transplant patients Donor leukocyte transfusions for treatment of recurrent chronic

  2011cites this paper
• hematopoietic progenitors in chronic myeloid leukemia BCR-ABL gene rearrangement and expression of primitive

  2011cites this paper
• following interferon therapy Philadelphia chromosome-positive chronic myelogenous leukemia Detection of minimal residual disease by polymerase chain reaction in

  2011cites this paper
• Interferon: Current Status and Future Prospects in Cancer Therapy

  2011cites this paper
• selection against the IFN system the IFN alpha/beta genes in acute leukemia cell lines suggests Correlation between interferon (IFN) alpha resistance and deletion of

  2011cites this paper
• Direct Effects of Type I Interferons on Cells of the Immune System

  2011cites this paper
• Lambda Interferons: New Cytokines with Old Functions

  2010cites this paper
• Antiproliferative Properties of Type I and Type II Interferon

  2010cites this paper
• Interferons: therapy for cancer

  2009cites this paper
• Optimizing first-line therapy for patients with chronic myeloid leukemia.

  2009cites this paper
• Interferon in chronic myeloid leukaemia: past and future.

  2009cites this paper
• Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.

  2009cites this paper
• [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].

  2008cites this paper
• [Bone marrow transplantation as therapy in chronic myeloid leukemia].

  2008cites this paper
• Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

  2008cites this paper
• Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.

  2008cites this paper
• [Transplantation of bone marrow from unrelated donors in chronic myeloid leukemia].

  2008cites this paper
• Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate

  2007cites this paper
• The role of interferon-alpha in the treatment of chronic myeloid leukemia.

  2007cites this paper
• Monitoring your patients with chronic myeloid leukemia.

  2006cites this paper
• Chronic myeloid leukemia: standard treatment options.

  2006cites this paper
• Exacerbation of Thyroid Autoimmunity b Treatment in Patients with Chronic Viral Studies and Review of the Literature y Interferon a' Hepatitis: Our

  2006cites this paper
• Symposiumon Recent Progress in Chemotherapy of Leukemia 1 ) Moderator : Torn

  2006cites this paper
• Chronic myeloid leukemia: changing the treatment paradigms.

  2006cites this paper
• Surface Antigens Proliferation of Hairy Cells Coincides with Modulation of Cell-Interferon-inhibited α B-Cell Growth Factor-induced and Updated Version

  2006cites this paper
• LONG-TERM EFFECT OF HOMOHARRINGTONIN E CHRONIC GRANULOCYTIC LEUKEMIA

  2005cites this paper
• CD34+CD7+ leukemic progenitor cells may be involved in maintenance and clonal evolution of chronic myeloid leukemia.

  2005cites this paper
• Long-term effect of homoharringtonine on chronic granulocytic leukemia

  2005cites this paper
• Fluorescence In Situ Hybridization Monitoring of BCR-ABL-Positive Neutrophils in Chronic-Phase Chronic Myeloid Leukemia Patients during the Primary Stage of Imatinib Mesylate Therapy

  2005cites this paper
• Chronic Myelogenous Leukemia-Progress at the M . D . Anderson Cancer Center over the Past Two Decades and Future Directions : First

  2005cites this paper
• Chronic Myelogenous Leukemia-Progress at the M. D. Anderson Cancer Center over the Past Two Decades and Future Directions: First Emil J Freireich Award Lecture1

  2005cites this paper
• CD 34 + CD 7 + Leukemic Progenitor Cells May Be Involved in Maintenance and Clonal Evolution of Chronic Myeloid Leukemia

  2005cites this paper
• CD34CD7 Leukemic Progenitor Cells May Be Involved in Maintenance and Clonal Evolution of Chronic Myeloid Leukemia

  2005cites this paper
• Multicenter Prospective Study of Interferon α versus Allogeneic Stem Cell Transplantation for Patients with New Diagnoses of Chronic Myelogenous Leukemia

  2004cites this paper
• Clinical and epidemiologic burden of chronic myelogenous leukemia

  2004cites this paper
• Table 2 . The Role of Cytoklnes In InflammatIon and RepaIr Acute inflammation

  2004cites this paper
• Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature.

  2004cites this paper
• Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.

  2004cites this paper
• Interferon therapy in chronic myelogenous leukemia.

  2004cites this paper
• Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a

  2004cites this paper
• Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.

  2003cites this paper
• [Cytogenetic remission 10 years after the start of monotherapy with interferon alpha-2b in elderly chronic myelogenous leukemia].

  2003cites this paper
• Recovery of Normal Hematopoiesis after Severe Bone Marrow Aplasia Induced by Interferon-α in a Patient with Chronic Myelogenous Leukemia

  2003cites this paper
• Treatment of CML using IFN-alpha: impact on quality of life.

  2003cites this paper
• Cancer biotherapy: 2003 disease-related activity

  2003cites this paper
• Chronic Myelogenous Leukemia : A Concise Update

  2003cites this paper
• G remissions of chronic myelogenous leukemia Polyclonal hematopoiesis in interferon-induced cytogenetic

  2003cites this paper
• Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis

  2003cites this paper
• A Randomized Trial Comparing Interferon-a! With Busulfan for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

  2002cites this paper
• Randomized Comparison of Interferon-a With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia

  2002cites this paper
• The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.

  2002cites this paper
• Interferon-cu and Hydroxyurea in Early Chronic Myeloid Leukemia: A Comparative Analysis of the Italian and German Chronic Myeloid Leukemia Trials With Interferon-cu

  2002cites this paper